8-K: Encompass Health Boosts Full-Year Guidance on Strong Q3 Performance

Encompass Health Corporation reported robust third-quarter 2025 results, exceeding expectations and prompting an increase in its full-year financial guidance.

Summary

• Net operating revenue for Q3 2025 increased by 9.4% to $1,477.5 million, compared to $1,351.0 million in Q3 2024.
• Diluted earnings per share from continuing operations rose by 15.9% to $1.24 in Q3 2025, up from $1.07 in Q3 2024.
• Adjusted EBITDA grew by 11.4% to $300.1 million for Q3 2025, compared to $269.3 million in the prior year's quarter.
• The company increased its full-year 2025 guidance for net operating revenue to a range of $5,905 million to $5,955 million.
• Full-year 2025 Adjusted EBITDA guidance was raised to $1,235 million to $1,255 million.
• Adjusted earnings per share guidance for full-year 2025 was increased to $5.22 to $5.37.
• Discharges increased by 5.0% to 65,839 in Q3 2025, with same-store discharge growth of 2.9%.
• Net patient revenue per discharge increased by 3.3% to $21,679.
• During Q3 2025, Encompass Health opened three new hospitals and added 39 beds to existing facilities, totaling 140 new beds.
• The company retired the remaining $100 million of its 5.75% Senior Notes due 2025.
• A quarterly dividend of $0.19 per share was paid in October 2025, following $0.17 per share dividends in January, April, and July 2025.
• Encompass Health repurchased 221,301 shares of common stock for $24.9 million in Q3 2025, with $408 million remaining under the current authorization as of September 30, 2025.

Sentiment

Score: 8

Explanation: The filing presents strong financial results for Q3 2025, with significant increases in revenue, EBITDA, and EPS. The company also raised its full-year guidance, indicating positive momentum and confidence in future performance. Continued capacity expansion and shareholder returns further contribute to a highly positive sentiment, despite a slight decrease in adjusted free cash flow for the quarter.

Positives

• Net operating revenue increased by 9.4% in Q3 2025 and 10.6% year-to-date, demonstrating strong top-line growth.
• Adjusted EBITDA increased by 11.4% in Q3 2025 and 14.5% year-to-date, indicating improved operational profitability.
• Adjusted earnings per share rose by 19.4% in Q3 2025 and 22.4% year-to-date, reflecting enhanced shareholder value.
• The company increased its full-year 2025 guidance across net operating revenue, Adjusted EBITDA, and adjusted earnings per share, signaling confidence in future performance.
• Capacity expansion continued with the opening of three new hospitals and the addition of 39 beds to existing facilities in Q3 2025, supporting future growth.
• Same-store discharge growth of 2.9% and a 3.3% increase in net patient revenue per discharge highlight effective utilization and pricing strategies.
• The net leverage ratio of 2.0x indicates a healthy balance sheet and effective debt management, further strengthened by the retirement of $100 million in Senior Notes.
• Consistent shareholder returns through quarterly dividends and ongoing share repurchases, with $408 million remaining under authorization.

Negatives

• Adjusted free cash flow decreased by 8.2% to $174.2 million in Q3 2025 compared to $189.7 million in Q3 2024, primarily due to increased working capital and maintenance capital expenditures.
• Working capital increased by $55.8 million in Q3, partly due to accelerated payment of accounts payable in preparation for the Oracle Fusion conversion.

Risks

• Infectious disease outbreaks could decrease patient volumes and revenues, and lead to staffing and supply shortages and associated cost increases.
• Demand for services may be negatively impacted by downturns in the economy, consumer confidence, or capital markets.
• Adverse outcomes from various lawsuits, claims, and legal or regulatory proceedings could affect financial results.
• Potential disruptions, breaches, or other incidents affecting information systems could lead to data theft or inability to provide patient care.
• Ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with growth strategy.
• Increases in Medicare audit activity, including sampling and extrapolation, could result in additional unpaid reimbursement claims and a backlog of appealed claims denials.
• Changes, delays, or suspension of reimbursement for services by governmental or private payors.
• Changes in healthcare industry regulation at federal and state levels, including national healthcare reform and deficit reduction, and the ability to adapt operations to these changes.
• Competitive pressures in the healthcare industry.
• Ability to obtain and retain favorable arrangements with third-party payors.
• Ability to control costs, particularly labor and employee benefit costs, including group medical expenses.
• Adverse effects from coverage determinations by Medicare Administrative Contractors and delays in recovering improperly denied claims.
• Ability to adapt to changes in the healthcare delivery system, such as value-based purchasing and coordinated care initiatives.
• Ability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with staffing shortages, and the impact of potential union activity.
• General conditions in the economy and capital markets, including instability related to trade wars, armed conflict, terrorism, governmental impasse, or debt crises.
• Increase in the cost or decrease in the availability of construction materials and necessary supplies, potentially due to tariffs and import restrictions.
• Increase in the costs of defending and insuring against alleged professional liability claims.

Future Outlook

Encompass Health has increased its full-year 2025 guidance for net operating revenue, Adjusted EBITDA, and adjusted earnings per share, reflecting strong performance and confidence in continued growth. The company plans to open 8 new hospitals (7 de novo and 1 satellite) and add approximately 127 beds to existing hospitals in 2025, with further de novo and satellite hospital developments planned through 2027. Key considerations for the outlook include anticipated Medicare pricing increases of approximately 2.9% for Q4, Managed Care pricing increases of approximately 3.0%, and a projected 3.25% increase in salaries and benefits per FTE. The company expects net pre-opening and ramp-up costs for new facilities to be between $18 million and $22 million for the full year.

Management Comments

• "During the quarter, we further increased our capacity to serve patients in need of inpatient rehabilitation care by opening three new hospitals and adding 39 beds to existing hospitals."
• "Our value proposition and operating strategy continue to be validated and we remain highly optimistic about the long-term prospects of our business."
• "Encompass Health was recently named Americas Most Awarded Leader in Inpatient Rehabilitation by Newsweek and Statista for the sixth consecutive year. Our consistent presence on this prestigious list reflects our long-standing commitment to delivering high-quality patient care and excellent outcomes."

Industry Context

Encompass Health operates as the largest owner and operator of inpatient rehabilitation hospitals in the United States, a sector characterized by a large, underpenetrated, and growing market driven by favorable demographics. The company's consistent capacity expansion strategy, including de novo hospitals and bed additions, aligns with the increasing demand for rehabilitation services. Its recognition as 'America's Most Awarded Leader in Inpatient Rehabilitation' and inclusion in 'Fortune's World's Most Admired Companies' and 'Forbes Most Trusted Companies in America' underscores its strong market position and perceived quality within the healthcare industry.

Comparison to Industry Standards

• Encompass Health was named 'America's Most Awarded Leader in Inpatient Rehabilitation by Newsweek and Statista for the sixth consecutive year', indicating sustained leadership in quality and outcomes within its specialized segment.
• The company is ranked among 'Fortune's World's Most Admired CompaniesTM' and 'Forbes Most Trusted Companies in America', suggesting strong corporate reputation and stakeholder trust relative to broader industry benchmarks.

Related Party Transactions

• The addition of the Augusta, GA, hospital to the Piedmont joint venture is expected to increase income attributable to noncontrolling interests (NCI) by approximately $6.0 million in 2025.

Stakeholder Impact

• Shareholders are positively impacted by increased earnings per share, higher full-year guidance, consistent dividend payments, and ongoing share repurchases.
• Employees may benefit from continued company growth and expansion, though labor costs are a focus for management.
• Patients will benefit from increased capacity and access to inpatient rehabilitation care through new hospital openings and bed additions.
• Creditors benefit from a healthy balance sheet and effective debt management, including the retirement of Senior Notes, which reduces overall debt.

Next Steps

• Host an investor conference call on October 30, 2025, to discuss Q3 2025 results.
• Continue with planned capacity additions, including 8 new hospitals and approximately 127 beds to existing hospitals in 2025.
• Proceed with de novo hospital developments in Athens, GA; Fort Myers, FL; St. Petersburg, FL; Amarillo, TX; Lake Worth, FL; Irmo, SC; Concordville, PA; Loganville, GA; Norristown, PA; San Antonio, TX; Bangor, ME; Avondale, AZ; Wesley Chapel, FL; St. George, UT; Apollo Beach, FL; Haslet, TX; North Las Vegas, NV; and Palm Beach Gardens, FL, with expected open dates through 2027.
• Manage Oracle Fusion implementation costs and post-implementation support expenses.
• Continue to execute on the stock repurchase authorization, with approximately $408 million remaining as of September 30, 2025.

Key Dates

Recommendation

The company delivered strong Q3 2025 financial results, surpassing prior year figures across key metrics like net operating revenue, Adjusted EBITDA, and adjusted EPS. The decision to raise full-year 2025 guidance for all major financial indicators signals robust operational performance and management's confidence in sustained growth. Strategic capacity expansion through new hospital openings and bed additions, coupled with a healthy balance sheet (net leverage of 2.0x) and ongoing shareholder returns (dividends and share repurchases), positions Encompass Health favorably. While adjusted free cash flow saw a slight quarterly dip, the overall trajectory and future outlook are highly positive, making it an attractive investment.

Keywords

Inpatient Rehabilitation, Healthcare Services, SEC Filing, Financial Results, Earnings, EBITDA, Guidance Update, Hospital Expansion, Patient Care, Corporate Governance, Risk Management, NYSE: EHC